Amsurg Corp. (NASDAQ:AMSG) has been given a $90.00 price target by stock analysts at Cantor Fitzgerald in a research report issued on Wednesday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s price target points to a potential upside of 35.91% from the stock’s current price.
Several other analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Amsurg Corp. from a “hold” rating to a “buy” rating and set a $88.00 price objective for the company in a research note on Monday, July 11th. Wells Fargo & Co. upgraded shares of Amsurg Corp. from a “market perform” rating to an “outperform” rating in a report on Wednesday, November 2nd. They noted that the move was a valuation call. KeyCorp reiterated a “positive” rating and issued a $87.00 target price on shares of Amsurg Corp. in a report on Tuesday, October 4th. Finally, Citigroup Inc. assumed coverage on shares of Amsurg Corp. in a report on Monday, September 26th. They issued a “buy” rating and a $79.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Amsurg Corp. has an average rating of “Buy” and an average target price of $89.45.
Shares of Amsurg Corp. (NASDAQ:AMSG) traded up 0.71% during trading on Wednesday, hitting $66.22. 296,468 shares of the stock were exchanged. The stock’s 50 day moving average price is $64.34 and its 200-day moving average price is $70.20. The company has a market cap of $3629.12 billion, a price-to-earnings ratio of 17.20 and a beta of 0.67. Amsurg Corp. has a one year low of $57.32 and a one year high of $86.17.
Amsurg Corp. (NASDAQ:AMSG) last released its earnings results on Tuesday, November 1st. The company reported $1.13 EPS for the quarter, hitting analysts’ consensus estimates of $1.13. The business earned $822.20 million during the quarter, compared to analysts’ expectations of $770.29 million. Amsurg Corp. had a net margin of 6.06% and a return on equity of 8.05%. The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.03 earnings per share. On average, analysts predict that Amsurg Corp. will post $4.31 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. Emerald Acquisition Ltd. acquired a new stake in Amsurg Corp. during the second quarter worth about $106,000. Rockefeller Financial Services Inc. acquired a new stake in Amsurg Corp. during the third quarter worth about $106,000. Acrospire Investment Management LLC raised its stake in Amsurg Corp. by 46.2% in the third quarter. Acrospire Investment Management LLC now owns 1,900 shares of the company’s stock worth $127,000 after buying an additional 600 shares during the period. Smith Asset Management Group LP raised its stake in Amsurg Corp. by 8,500.0% in the second quarter. Smith Asset Management Group LP now owns 1,720 shares of the company’s stock worth $133,000 after buying an additional 1,700 shares during the period. Finally, Invictus RG raised its stake in Amsurg Corp. by 824.3% in the first quarter. Invictus RG now owns 1,904 shares of the company’s stock worth $142,000 after buying an additional 1,698 shares during the period. Institutional investors own 98.67% of the company’s stock.
Amsurg Corp. Company Profile